{"id":"gsk3511294-depemokimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL4650469","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-4Rα is a key component of both IL-4 and IL-13 signaling pathways, which drive type 2 inflammation. By blocking this receptor, depemokimab reduces the production of IgE and other markers of allergic and eosinophilic inflammation. This mechanism is intended to treat conditions characterized by excessive type 2 immune responses.","oneSentence":"Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:39.498Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe atopic dermatitis"},{"name":"Eosinophilic esophagitis"}]},"trialDetails":[{"nctId":"NCT07456033","phase":"PHASE3","title":"A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-06","conditions":"Asthma","enrollment":456},{"nctId":"NCT05243680","phase":"PHASE3","title":"An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-01","conditions":"Asthma","enrollment":641},{"nctId":"NCT05274750","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-04-22","conditions":"Nasal Polyps","enrollment":276},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT06959095","phase":"PHASE3","title":"Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-06-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":981},{"nctId":"NCT05281523","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-04-18","conditions":"Nasal Polyps","enrollment":264},{"nctId":"NCT06961214","phase":"PHASE3","title":"Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-06-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":960},{"nctId":"NCT04719832","phase":"PHASE3","title":"Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-03-17","conditions":"Asthma","enrollment":395},{"nctId":"NCT04718103","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-02-04","conditions":"Asthma","enrollment":397}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK3511294 (Depemokimab)","genericName":"GSK3511294 (Depemokimab)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses. Used for Moderate-to-severe atopic dermatitis, Eosinophilic esophagitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}